

Div Gupta

Partner



dgupta@cooley.com

+1 212 479 6474

New York

Capital Markets
Public Companies
Life Sciences
Technology

Div Gupta's practice focuses on the representation of public and private emerging growth companies and investment banking firms. He has handled a variety of significant business transactions, including public offerings of equity, high yield debt and convertible debt, venture capital financings and mergers and acquisitions. He also advises a number of private companies as well as public companies on securities and general corporate matters. Div is ranked in Legal 500 and Chambers USA for his work in Capital Markets, Life Sciences and Healthcare, and has been named by Law360 as a Rising Star in Capital Markets and recognized by Who's Who Legal as a leading life sciences lawyer. Div is consistently among the nation's leaders in IPOs and other capital markets transactions run year after year. Clients describe him as "collaborative, helpful and productive" noting that he is "very solutions-oriented" and "a pleasure to work with."

Div's representative transactions include:

- Immunocore on a \$273 million IPO and listing on Nasdaq
- Orphazyme A/S in its \$83.8 million initial public offering
- Taysha Gene Therapies in its \$181.0 million initial public offering
- Inventiva in its \$108.0 million initial public offering
- PolyPid in its \$69.0 million initial public offering
- Repare Therapeutics in its \$253.0 million initial public offering
- Legend Biotech in its \$487.3 million initial public offering
- Gamida Cell in its \$69.0 million follow-on offering
- Oyster Point Pharma in its \$105.0 million follow-on offering
- Innate Pharma in its \$79.1 million initial public offering
- Castle Biosciences in its \$73.6 million initial public offering
- Prevail Therapeutics in its \$125.0 million initial public offering
- Milestone Pharmaceuticals in its \$94.9 million initial public offering
- Applied Therapeutics in its \$40.0 million initial public offering
- Gamida Cell in its \$53.2 million initial public offering
- Neuronetics in its \$107.5 million initial public offering

- ObsEva in its \$73.1 million follow-on offering
- Verrica Pharmaceuticals in its \$86.3 million initial public offering
- AveXis in its \$460.0 million follow-on offering
- ERYTECH Pharma in its \$143.7 million initial public offering
- Nightstar Therapeutics in its \$86.0 million initial public offering
- Dova Pharmaceuticals in its \$75.1 million initial public offering
- Ovid Therapeutics in its \$75.0 million initial public offering
- Biohaven in its \$193.6 million initial public offering
- ObsEva in its \$96.8 million initial public offering
- AveXis in its \$105.0 million initial public offering
- Axovant Sciences Ltd. in its \$362.3 million initial public offering
- Bellicum Pharmaceuticals in its \$160.6 million initial public offering

Advising underwriters, including BofA Securities, Barclays, BMO, Canaccord, Cowen, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, Jefferies, JMP Securities, J.P. Morgan, Lazard, SVB Leerink, Morgan Stanley, Needham, Nomura, Oppenheimer, Piper Sandler, RBC, Stifel Nicolaus, Wedbush, Wells Fargo and William Blair, on a wide number of transactions, including the following recent transactions:

- \$250.0 million follow-on public offering by SpringWorks Therapeutics
- \$209.8 million initial public offering by C4 Therapeutics
- \$48.3 million follow-on public offering by LogicBio Therapeutics
- \$204.0 million follow-on public offering by ADC Therapeutics
- \$181.9 million initial public offering by Prelude Therapeutics
- \$146.6 million initial public offering by COMPASS Pathways
- \$267.7 million initial public offering by Dyne Therapeutics
- \$379.5 million follow-on public offering by Schrodinger
- \$144.4 million follow-on public offering by Zentalis Pharmaceuticals
- \$201.1 million initial public offering by iTeos Therapeutics
- \$132.2 million follow-on offering by Altimune
- \$216.4 million follow-on offering by Akero Therapeutics
- \$83.8 million follow-on offering by 89bio
- \$690.0 million follow-on offering by Ascendis Pharma
- \$275.1 million follow-on offering by Translate Bio
- \$244.4 million initial public offering by Akouos
- \$275.1 million follow-on offering by Translate Bio
- \$298.1 million initial public offering by Avidity Biosciences
- \$90.0 million initial public offering by Calliditas Therapeutics
- \$862.5 million follow-on offering by argenX
- \$232.7 million initial public offering by ADC Therapeutics

- \$190.0 million initial public offering by Zentaris Pharmaceuticals
- \$75.2 million initial public offering by Imara
- \$216.0 million initial public offering by Passage Bio
- \$232.3 million initial public offering by Schrodinger
- \$404.2 million follow-on offering by Apellis Pharmaceuticals
- \$505.0 million follow-on offering by Reata Pharmaceuticals
- \$96.7 million initial public offering by 89bio
- \$556.6 million follow-on offering by argenX
- \$186.3 million initial public offering by Springworks Therapeutics
- \$102.6 million initial public offering by Karuna Therapeutics
- \$103.5 million initial public offering by Morpheic Therapeutic
- \$105.8 million initial public offering by Akero Therapeutics
- \$60.7 million initial public offering by Bicycle Therapeutics
- \$86.3 million initial public offering by NextCure
- \$145.4 million initial public offering by Precision Biosciences
- \$78.0 million initial public offering by Stealth BioTherapeutics
- \$255.6 million initial public offering by Tricida
- \$121.6 million initial public offering by Translate Bio
- \$100.0 million initial public offering by Neon Therapeutics
- \$122.2 million initial public offering by Eidos Therapeutics
- \$180.0 million initial public offering by Surface Oncology
- \$150.0 million initial offering by Apellis Pharmaceuticals

Div Gupta serves on the board of advisors of Life Sciences Cares NY, an organization that activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities, and the board of trustees of Oliver Scholars, an organization that prepares high-achieving Black and Latinx students from underserved New York City communities for success at top independent schools and prestigious colleges.

Prior to joining Cooley, Div was a partner at Latham & Watkins. Prior to joining Latham, he was a corporate associate with Covington & Burling in New York, and he began his career as a corporate associate in Brobeck, Phleger & Harrison's New York office.

Education

Harvard Law School
JD, 2000

Yale University
BS, 1997

Admissions & Credentials

California

New York

Texas

Rankings & Accolades

Chambers USA: Life Sciences: Corporate/Commercial – Nationwide (2022 – 2023)

Chambers USA: Capital Markets: Debt & Equity: Eastern United States – Nationwide (2020 – 2023)

Legal 500: Key Lawyer - Capital Markets: Equity Offerings and Healthcare: Life Sciences (2020 – 2021)

Law 360 Rising Star (2015)

Who's Who Legal: Life Sciences (2018)